EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors

Adriana M Kahn iD, Curtis J Perry, Katrina Etts, Harriet Kluger, Mario Sznol iD

The Oncologist · 04.04.2024 · 29 (4) · e507-e513

DOI: 10.1093/oncolo/oyad300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 16.11.2023. Verfasst von Adriana M Kahn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prospective and between trial comparisons indicate that first-line treatment with immune checkpoint inhibitors improves survival outcomes compared to first-line therapy with combined BRAF and MEK inhibitors in metastatic melanoma containing BRAFV600E/K mutations. Long-term outcomes for BRAF/MEK inhibition after progression on immunotherapy have not been reported. Moreover, clinical variables associated with outcome from treatment with combined BRAF/MEK inhibition were previously identified in the first-line setting but have not been investigated when targeted therapies are administered after progression on immune therapy. We performed a retrospective single institution analysis of 40 metastatic melanoma patients receiving combined BRAF/MEK inhibitors after progression on an anti-PD-1 or ipilimumab plus nivolumab to assess response rate by RECIST 1.1, progression-free and overall survival (PFS and OS). Pretreatment clinical variables were analyzed for association with OS. Ipilimumab/nivolumab was the first-line immunotherapy regimen in 39 patients (97.5%), and BRAFV600E/K mutations were present in 33 (83%) and 7 (17%) patients, respectively. The median OS from start of BRAF/MEK inhibitors was 20.3 months (1.73-106.4+, 95% CI of median 13.3-30.7). Clinical characteristics associated with worse survival prior to starting BRAF/MEK inhibitors included age > 60 years (median OS 14 vs. 28 months; HR 2.5; 95% CI 0.91-6.87, P = .023), ECOG-PS > 2 (median OS 7 vs. 33 months; HR 2.89; 95% CI 0.78-10.76, P = .018), and presence of bone metastases (median OS 9 vs. 52 months; HR 3.17; 95% CI 1.33-7.54, P = .002). These associations with shorter survival maintained their significance on multivariate analysis. If confirmed in larger cohorts, the identified prognostic variables can be used for stratification of patients in future randomized trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansMiddle AgedImmune Checkpoint InhibitorsIpilimumabProto-Oncogene Proteins B-rafNivolumabRetrospective StudiesProspective StudiesProtein Kinase InhibitorsMitogen-Activated Protein Kinase KinasesAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

immunotherapymelanomasurvivaltargeted therapy

Substanzen

Immune Checkpoint InhibitorsIpilimumabProto-Oncogene Proteins B-rafNivolumabProtein Kinase InhibitorsMitogen-Activated Protein Kinase KinasesBRAF protein, human

Autor:innen und Institutionen

  • Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.

ORCID-Profile: Adriana M Kahn, Mario Sznol

Förderung

  • NCATS NIH HHS

Zitieren

APA

Kahn, A. M., Perry, C. J., Etts, K., Kluger, H., & Sznol, M. (2024). Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. The Oncologist, 29(4), e507-e513. https://doi.org/10.1093/oncolo/oyad300

Vancouver

Kahn AM, Perry CJ, Etts K, Kluger H, Sznol M. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. The Oncologist. 2024;29(4):e507-e513. doi:10.1093/oncolo/oyad300

BibTeX
@article{Kahn2024,
  author = {Kahn, Adriana M and Perry, Curtis J and Etts, Katrina and Kluger, Harriet and Sznol, Mario},
  title = {Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {4},
  pages = {e507--e513},
  doi = {10.1093/oncolo/oyad300}
}
Kostenlos starten →